IRIS UniCatt

Giampietro, Antonella
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.419
EU - Europa 3.045
AS - Asia 2.656
SA - Sud America 778
AF - Africa 82
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 5
AN - Antartide 1
Totale 9.992
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.283
SG - Singapore 1.249
DE - Germania 1.117
CN - Cina 700
BR - Brasile 646
SE - Svezia 424
IT - Italia 394
VN - Vietnam 202
FR - Francia 184
UA - Ucraina 183
GB - Regno Unito 156
IE - Irlanda 120
RU - Federazione Russa 114
FI - Finlandia 103
ID - Indonesia 101
IN - India 94
PL - Polonia 83
CA - Canada 69
AR - Argentina 53
HK - Hong Kong 42
MX - Messico 40
NL - Olanda 38
IQ - Iraq 36
BD - Bangladesh 35
TR - Turchia 31
JP - Giappone 29
AT - Austria 27
ES - Italia 26
BE - Belgio 25
ZA - Sudafrica 23
EC - Ecuador 20
KR - Corea 18
VE - Venezuela 16
IR - Iran 15
CO - Colombia 13
EG - Egitto 13
PK - Pakistan 13
AE - Emirati Arabi Uniti 12
SA - Arabia Saudita 12
UZ - Uzbekistan 11
MA - Marocco 10
CI - Costa d'Avorio 9
CL - Cile 9
PE - Perù 9
KE - Kenya 8
KZ - Kazakistan 8
PY - Paraguay 8
CZ - Repubblica Ceca 7
PT - Portogallo 7
AL - Albania 6
AZ - Azerbaigian 6
JM - Giamaica 6
LK - Sri Lanka 6
JO - Giordania 5
MD - Moldavia 5
NP - Nepal 5
BG - Bulgaria 4
DO - Repubblica Dominicana 4
HN - Honduras 4
RO - Romania 4
TN - Tunisia 4
BH - Bahrain 3
CH - Svizzera 3
CR - Costa Rica 3
ET - Etiopia 3
EU - Europa 3
GE - Georgia 3
LB - Libano 3
OM - Oman 3
RS - Serbia 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AU - Australia 2
BB - Barbados 2
BO - Bolivia 2
BS - Bahamas 2
BY - Bielorussia 2
GA - Gabon 2
GH - Ghana 2
GR - Grecia 2
KG - Kirghizistan 2
MY - Malesia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PH - Filippine 2
UY - Uruguay 2
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BW - Botswana 1
DK - Danimarca 1
GT - Guatemala 1
GU - Guam 1
HU - Ungheria 1
IL - Israele 1
KW - Kuwait 1
LI - Liechtenstein 1
LT - Lituania 1
LV - Lettonia 1
Totale 9.979
Salva come PNG Salva come JPEG
Città #
Chandler 582
Singapore 582
Ashburn 312
New York 158
Beijing 154
Los Angeles 121
Dublin 112
San Mateo 108
Rome 102
Jakarta 84
Ann Arbor 82
Hefei 80
Ho Chi Minh City 79
Moscow 76
Munich 73
Warsaw 73
Jacksonville 72
São Paulo 70
Fairfield 68
Wilmington 68
Boston 61
Dallas 61
Marseille 61
Milan 59
Nürnberg 55
The Dalles 54
Nanjing 48
Frankfurt am Main 46
Houston 46
Bremen 44
Seattle 42
Cattolica 40
Hanoi 40
Hong Kong 40
Princeton 40
Helsinki 37
Dearborn 34
Montreal 33
Chicago 31
Redwood City 31
Kent 30
Woodbridge 29
Denver 28
London 28
Turku 26
Brussels 24
Nanchang 24
Santa Clara 24
Cambridge 23
Shanghai 23
Nuremberg 22
Boardman 21
Brooklyn 21
Hangzhou 21
Lawrence 21
Mountain View 20
Rio de Janeiro 20
Zhengzhou 19
Buffalo 18
Hyderabad 17
Tokyo 17
University Park 17
Belo Horizonte 16
North Bergen 16
Orem 15
Seoul 15
Shenyang 15
Fremont 14
Guangzhou 14
Augusta 13
Vienna 13
Baghdad 12
Düsseldorf 12
Johannesburg 12
Mumbai 12
Norwalk 12
Phoenix 12
Poplar 12
Stockholm 12
Toronto 12
Bexley 11
Dhaka 11
Kunming 11
Lappeenranta 11
Lauterbourg 11
Leawood 11
Porto Alegre 11
Santo André 11
Atlanta 10
Hebei 10
Izmir 10
Mexico City 10
Tashkent 10
Tianjin 10
Abidjan 9
Changsha 9
Guayaquil 9
Kish 9
Lancaster 9
Manchester 9
Totale 4.893
Salva come PNG Salva come JPEG
Nome #
Hypophysitis Outcome and Factors Predicting Responsiveness to Glucocorticoid Therapy: A Prospective and Double-Arm Study. 277
Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review 276
Double pituitary adenomas 225
Role of a mini-invasive approach in the diagnosis and treatment of tubo-peritoneal infertility as an altenative to IVF [Il ruolo di un approccio chirurgico mini-invasivo nella diagnosi e trattamento della sterilità tubo-peritoneale in alternativa alla FIVET] 193
Coenzyme Q10 evaluation in pituitary-adrenal axis disease: preliminary data. 189
Non Alcoholic Fatty Liver Disease is Associated with Increased GHBP and Reduced GH/IGF-I Levels 186
Typical and Atypical Pituitary Adenomas: A Single-Center Analysis of Outcome and Prognosis 186
An Overview of Diagnosis of Primary Autoimmune Hypophysitis in a Single Prospective Monocentric Experience 177
Male fertility and reduction in semen parameters: A single tertiary-care center experience 176
Effects of gherlin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome 175
Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study 171
Circulating endothelial cells as marker of endothelial damage in male hypogonadism 168
NOVEL BIOMARKERS OF ANDROGEN DEFICIENCY FROM SEMINAL PLASMA PROFILING USING HIGH-RESOLUTION MASS SPECTROMETRY. 159
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: An immunohistochemical study 154
Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH/IGF-I levels 153
Isolated growth hormone deficiency: clinical entity? 147
Circulating endothelial cells as marker of endothelial damage in male hypogonadism 144
Influence of diabetes mellitus on vertebral fractures in men with acromegaly 138
Effects of ghrelin administration on endocrine and metabolic parameters in obese women with polycystic ovary syndrome 137
Radically resected pituitary adenomas: prognostic role of Ki67 labeling index in monocentric retrospective series and literature review 135
The Changing Clinical Spectrum of Hypophysitis 135
Significant GH-deficiency after long-term cure by surgery in adult patients with Cushing s disease 133
Glucocorticoid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency 130
The effect of treatment with growth hormone on fertility outcome in eugonadal women with growth hormone deficiency: report of four cases and review of the literature 127
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 127
Galectin-3 and Estrogen Receptor Alpha as Prognostic Markers in Prolactinoma: Preliminary Results From a Pilot Study 125
Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second Line Therapies: A Longitudinal Study 122
Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes 120
Fertility and hypopituitarism 116
Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. 114
DIAGNOSIS OF ENDOCRINE DISEASE: Primary Empty Sella: a comprehensive review 114
Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study 114
GH receptor isoforms and skeletal fragility in acromegaly 110
The changing clinical spectrum of endocrine adverse events in cancer immunotherapy 108
Synchronous Bilateral Adrenalectomy in ACTH-dependent Hypercortisolism: Predictors, Biomarkers and Outcomes 107
Quantitative Analysis of the Seminal Plasma Proteome in Secondary Hypogonadism 102
Empty sella syndrome: Multiple endocrine disorders. 102
First Case of Mature Teratoma and Yolk Sac Testis Tumor Associated to Inherited MEN-1 Syndrome. 100
Characteristics and outcomes of Italian patients from the observational, multicentre, hypopituitary control and complications study (HypoCCS) according to tertiles of growth hormone peak concentration following stimulation testing at study entry 99
Reappraising the Role of Trans-Sphenoidal Surgery in Prolactin-Secreting Pituitary Tumors. 98
Autoantibody reactivity profile of primary autoimmune hypophysitis patients: preliminary results 98
Pancreas as an Unusual Metastatic Site of Medullary Thyroid Carcinoma: A Case of Very Long-term Follow-up Under Prolonged Treatment with Somatostatin Analogues 95
Vertebral fractures in patients with acromegaly: a 3-year prospective study 93
Human leucocyte antigens coeliac haplotypes and primary autoimmune hypophysitis in caucasian patients 93
Neuro-radiological features can predict hypopituitarism in primary autoimmune hypophysitis 91
The Role of Growth Hormone Receptor Isoforms and Their Effects in Bone Metabolism and Skeletal Fragility 91
Aggressive PitNETs and Potential Target Therapies: A Systematic Review of Molecular and Genetic Pathways 90
Effects of Pegvisomant and Pasireotide LAR on Vertebral Fractures in Acromegaly Resistant to First-generation SRLs. 89
Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant 89
The Pathogenic RET Val804Met Variant in Acromegaly: A New Clinical Phenotype? 89
Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours 88
Growth hormone receptor isoforms and fracture risk in adult-onset growth hormone-deficient patients. 87
Hypothalamitis and pituitary atrophy 87
Effects of glucocorticoid replacement therapy in patients with pituitary disease: A new perspective for personalized replacement therapy 86
Unveiling the Etiopathogenic Spectrum of Hypophysitis: A Narrative Review 85
Understanding the effect of acromegaly on the human skeleton. 85
Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly. 83
Pituitary Enlargement and Hypopituitarism in Patients Treated with Immune Checkpoint Inhibitors: Two Sides of the Same Coin? 82
Clinical management of teratoma, a rare hypothalamic-pituitary neoplasia 80
Pregnancy in Autoimmune Hypophysitis: Management of a Rare Condition 78
Short- and long-term responsiveness to low dose growth hormone (GH) in adult GH deficiency: Role of GH receptor polymorphism. 77
The Differential Diagnosis between Pseudo Cushing's Syndrome and True Cushing's Syndrome in a Septic Patient in the Pre-Agonal Phase: A Case Report 76
Multidimensional geriatric evaluation in acromegaly: a comparative cross-sectional study 76
Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors 73
IGF-I levels during standard Lanreotide dose predicts biochemical outcome of high-frequency regimen in acromegaly 73
Genes of the “regulation of lymphocyte activation” pathway may influence immune cells infiltration in growth hormone secreting pituitary tumors 72
Prevalence of morphometric vertebral fractures in "difficult" patients with acromegaly with different biochemical outcomes after multimodal treatment. 72
Tumor features in adult papillary and adamantinomatous craniopharyngioma: neuroradiological evaluation of pituitary-hypothalamic-axis dysfunction and outcome prediction 70
Solitary Metastatic Melanoma of the Pituitary Gland: Report of Two Cases and Literature Review 70
Acromegaly can be cured by first-line pasireotide treatment? 70
Systemic comorbidities of acromegaly in real-life experience: which difference among young and elderly patients? 69
Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries 66
Acromegaly in the elderly patients 66
CD68+ and CD8+ immune cells are associated with the growth pattern of somatotroph tumors and response to first generation somatostatin analogs 64
The multi-biomarker acro-TIME score predicts fg-SRLs response: preliminary results of a retrospective acromegaly cohort 64
Trouillas's Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach 64
Empty sella syndrome: an update 63
De-escalation treatment with pasireotide for acromegaly: a long-term experience 63
GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study 61
Treatment of Acromegalic Osteopathy in Real-life Clinical Practice: The BAAC (Bone Active Drugs in Acromegaly) Study 61
Trouillas’s Grading and Post-Surgical Tumor Residue Assessment in Pituitary Adenomas: The Importance of the Multidisciplinary Approach 60
Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response 60
Factors associated with disease control failure in acromegaly patients treated with pegvisomant: an ACROSTUDY analysis 59
Cytokines and chemokines modulate the growth of pituitary adenoma/neuroendocrine tumors: preliminary results of a monocenter prospective pilot study 59
Colon Cancer Presenting as Pituitary Mass and Hypopituitarism: Recognition and Multidisciplinary Approach of a Rare Case 58
Clinical implications of the 2022 WHO classification on the multidisciplinary management of PitNETS patients 56
Psychological complications in patients with acromegaly: relationships with sex, arthropathy, and quality of life 56
Tumor features in adult papillary and adamantinomatous craniopharyngioma: neuroradiological evaluation of pituitary-hypothalamic-axis dysfunction and outcome prediction 56
Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences 53
Bone health and skeletal fragility in second- and third-line medical therapies for acromegaly: preliminary results from a pilot single center experience 52
Bone safety of dual-release hydrocortisone in patients with hypopituitarism. 51
A Toluene-induced Infundibulo-neuro-hypophysitis: Presentation of a New Cause of Hypophysitis Secondary to Toxic Exposure and Review on Toluene Inhalation Endocrine Effects 50
Markers of humoral and cell-mediated immune response in primary autoimmune hypophysitis: a pilot study 50
Second line treatment of acromegaly: Pasireotide or Pegvisomant? 48
Cholecalciferol Use Is Associated With a Decreased Risk of Incident Morphometric Vertebral Fractures in Acromegaly 45
The clinicopathological PANOMEN-3 classification predicts pituitary adenoma prognosis: a real-world retrospective single center study of a surgically treated cohort 41
Vitamin D in pituitary driven osteopathies 39
Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours 37
Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience 32
Use of 111In-pentetreotide scintigraphy for diagnosis and management of resistant macroprolactinoma 29
Totale 9.989
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.370
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.370
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021254 0 0 0 0 0 27 47 9 43 55 68 5
2021/2022617 30 33 7 47 74 27 10 112 28 26 85 138
2022/20231.516 173 207 123 252 80 211 89 127 157 13 53 31
2023/2024717 32 160 17 32 31 142 35 8 28 34 93 105
2024/20251.843 30 40 124 75 101 74 37 67 273 188 395 439
2025/20263.189 736 221 421 769 846 196 0 0 0 0 0 0
Totale 10.125